European Commission approves Teva’s $40.5bn acquisition of Allergan’s generics business
The commission had concerns that the merged entity would have faced insufficient competition from the other rivals for several generic drugs, particularly in the UK Ireland and Iceland.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.